NEW YORK (GenomeWeb News) – Life Technologies today said that it has signed a licensing and supply deal with VelaDx providing the Singapore-based firm rights to develop clinical diagnostic tests on Life Tech's Ion Personal Genome Machine platform.
Under the terms of the deal VelaDx will seek regulatory approvals from global authorities to sell clinical tests for oncology and infectious disease applications. Further terms of the alliance were not disclosed.
According to Life Tech, VelaDx's automated Sentosa workflow system and its menu of qPCR assay kits are complementary to the Ion Torrent platform. Its said that a seamless, bi-directional data communication with laboratory information systems between the Ion Torrent and Sentosa systems will improve workflow efficiency and maintain thew accuracy of data.
"Semiconductor sequencing is a transformative technology that can make diagnostic tests faster — a one-day turnaround — and more informative, helping doctors around the world save lives and make personalized medicine a reality," Ion Torrent President and COO Gregg Fergus said in a statement. "The founders and management team at Vela Diagnostics have a proven track record of first-mover success in the diagnostic marketplace and are ideal partners to introduce tests in the important clinical areas they have licensed."